CTAP
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction[1][2].
Product Specifications
CAS Number
103429-32-9
UNSPSC
12352209
Target
Opioid Receptor
Type
Peptides
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/ctap.html
Purity
99.30
Solubility
H2O : 1.67 mg/mL (ultrasonic)
Smiles
O=C([C@@H](NC([C@H](CSSC(C)([C@H](NC([C@](NC([C@@H](NC1=O)CCCNC(N)=N)=O)([H])[C@H](O)C)=O)C(N[C@H](C(N)=O)[C@H](O)C)=O)C)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=C(C=C3)O)N[C@@H]1CC4=CNC5=CC=CC=C45
Molecular Formula
C51H69N13O11S2
Molecular Weight
1104.30
References & Citations
[1] Mitchell J Bartlett, et al. Highly-selective µ-opioid Receptor Antagonism Does Not Block L-DOPA-induced Dyskinesia in a Rodent Model.BMC Res Notes|[2]Abbruscato TJ, et al. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine. J Pharmacol Exp Ther. 1997 Jan;280 (1) :402-9.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
δ Opioid Receptor/DOR; μ Opioid Receptor/MOR
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
